Original language | English (US) |
---|---|
Pages (from-to) | E220035 |
Journal | JAMA Network Open |
Volume | 5 |
Issue number | 2 |
DOIs | |
State | Published - Feb 25 2022 |
ASJC Scopus subject areas
- General Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JAMA Network Open, Vol. 5, No. 2, 25.02.2022, p. E220035.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs
AU - Shahid, Izza
AU - Khan, Muhammad Shahzeb
AU - Sohail, Aruba
AU - Khan, Safi U.
AU - Greene, Stephen J.
AU - Fudim, Marat
AU - Michos, Erin D.
N1 - Funding Information: Author Contributions: Dr Shahid had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Shahid, M.S. Khan, Fudim, Michos. Acquisition, analysis, or interpretation of data: Shahid, M.S. Khan, Sohail, S.U. Khan, Greene, Michos. Drafting of the manuscript: Shahid, Sohail. Critical revision of the manuscript for important intellectual content: M.S. Khan, S.U. Khan, Greene, Fudim, Michos. Statistical analysis: Shahid, Sohail. Obtained funding: Michos. Administrative, technical, or material support: M.S. Khan. Supervision: Shahid, M.S. Khan, Fudim, Michos. Conflict of Interest Disclosures: Dr Greene reported receiving research support from the American Heart Association; nonfinancial support from Amgen, AstraZeneca, Bristol-Myers Squibb, Cytokinentics, Merck, Novartis, Pfizer, and Sanofi; and personal fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Cytokinetics, Merck, Sanofi, and Vifor outside the submitted work. Dr Greene also reported serving on advisory boards for Amgen, AstraZeneca, and Cytokinetics and as a consultant for Amgen, Bayer, Merck, and Vifor. Dr Fudim reported receiving support from the National Heart, Lung, and Blood Institute, the American Heart Association, Bayer, and BTG Specialty Pharmaceuticals; the Mario Family Award, the Duke Chair’s Award, and the Translating Duke Health Award; and consulting fees from AstraZeneca, AxonTherapies, CVRx, Daxor, Edwards LifeSciences, Galvani, and NXT Biomedical. Dr Michos reported receiving personal fees from and serving on advisory boards for AstraZeneca, Bayer, Novo Nordisk, Novartis, Amarin, and Esperion outside the submitted work. No other disclosures were reported. Funding Information: Funding/Support: This work was supported by unrestricted research support from the Amato Fund for Women’s Cardiovascular Health at Johns Hopkins University (Dr Michos).
PY - 2022/2/25
Y1 - 2022/2/25
UR - http://www.scopus.com/inward/record.url?scp=85125552266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125552266&partnerID=8YFLogxK
U2 - 10.1001/jamanetworkopen.2022.0035
DO - 10.1001/jamanetworkopen.2022.0035
M3 - Letter
C2 - 35212753
AN - SCOPUS:85125552266
SN - 2574-3805
VL - 5
SP - E220035
JO - JAMA Network Open
JF - JAMA Network Open
IS - 2
ER -